Abstract
Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
Highlights
The treatment landscape of metastatic renal cell carcinoma dramatically changed with the introduction of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) [1]
Treatment breaks were incorporated into the development of VEGFR TKIs to limit toxicities, suggesting that continuous treatment is not always necessary and that extended periods off treatment might be feasible without compromising clinical outcomes
A retrospective analysis investigated whether patients with metastatic renal cell carcinoma (mRCC) treated with TKI who achieve complete response (CR) on treatment, can take a treatment break until relapse [2]
Summary
The treatment landscape of metastatic renal cell carcinoma (mRCC) dramatically changed with the introduction of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) [1]. A primary challenge with TKIs is the balance of clinical efficacy and associated toxicities of longterm therapy. Treatment breaks were incorporated into the development of VEGFR TKIs to limit toxicities, suggesting that continuous treatment is not always necessary and that extended periods off treatment might be feasible without compromising clinical outcomes.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
